Skip to main content

Feng Zhang spinout brings in $215M for gene editing

Nearly six years after launching from the lab of gene-editing pioneer Feng Zhang, Arbor Biotechnologies is charging ahead with a massive Series B round: $215 million co-led by Temasek, Ally Bridge Group and TCG Crossover.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.